Products

What will AGI do for Baquiloprim?

This classification denotes an antiprotozoal agent with the molecular formula C17H20N6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3DE766VIG6, chemically known as 5-((2,4-diamino-5-pyrimidinyl)methyl)-8-(dimethylamino)-7-methylquinoline but more generally known as baquiloprim, which bears US NIH Compound Identifier 72121. European Medicines Agency schedules Baquiloprim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06100MIG. The term BAQUILOPRIM is an International Non-Proprietary Name. BAQUILOPRIM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

How AGI delivers it

Four ways AGI delivers for Baquiloprim

  • Headless SaaS for Agents

    Give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

    For Baquiloprim, give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

  • Services-as-Software

    Get the professional outcome delivered as software, priced on results, not headcount.

    For Baquiloprim, get the professional outcome delivered as software, priced on results, not headcount.

Value flow

How Baquiloprim connects

measured by

  • Assay Puritymodel
  • Melting Pointmodel
  • Particle Size Distributionmodel
  • Residual Solventmodel